Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 52 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hyperkalaemia Clear all
Terminated Phase 4 Interventional Results available

Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Add-On

NCT03597035
View directory record Official record
Conditions
Type2 Diabetes, Hyperkalemia
Interventions
Spironolactone
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
45 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 15, 2022 · Synced Jul 22, 2026, 9:18 AM EDT
Completed No phase listed Observational

REal World EVidence for TrEAtment of HyperkaLemia in Emergency Department: Multicenter, Prospective, Observational Study

NCT02607085
View directory record Official record
Conditions
Hyperkalemia
Interventions
Not listed
Lead sponsor
ZS Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
Montgomery, Alabama • Detroit, Michigan • Royal Oak, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Jul 22, 2026, 9:18 AM EDT
Not listed Phase 1 Interventional

Potassium Binder in CKD Patients (With Hyperkalemia) (DiPo Trial)

NCT04727840
View directory record Official record
Conditions
Chronic Kidney Diseases, Hyperkalemia
Interventions
Sodium Zirconium Cyclosilicate Oral Product
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Jul 22, 2026, 9:18 AM EDT
Terminated Phase 3 Interventional Results available

Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease

NCT04727528
View directory record Official record
Conditions
Hyperkalaemia, Metabolic Acidosis, Chronic Kidney Disease
Interventions
Sodium zirconium cyclosilicate, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
29
States / cities
Florence, Alabama • Chula Vista, California • Downey, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Jul 22, 2026, 9:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Relationship Between Potassium Level in Venous Blood Samples Drawn and Heel Sticks In Infants and Newborns

NCT01349218
View directory record Official record
Conditions
Hyperkalemia
Interventions
Blood sample drawn from a vein, Blood sample drawn from a heel stick
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Up to 6 Months
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Jul 22, 2026, 9:18 AM EDT
Completed Phase 3 Interventional Results available

Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months

NCT02163499
View directory record Official record
Conditions
Hyperkalemia
Interventions
Sodium Zirconium Cyclosilicate
Drug
Lead sponsor
ZS Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
36
States / cities
Scottsboro, Alabama • Tempe, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Jul 22, 2026, 9:18 AM EDT
Completed No phase listed Observational

A Study to Detect Hyperkalemia Using Smartphone-enabled Electrocardiogram (EKG)

NCT05441852
View directory record Official record
Conditions
Hyperkalemia
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 89 Years
Enrollment
1,151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Jul 22, 2026, 9:18 AM EDT
Completed Phase 2 Interventional

A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia

NCT04780841
View directory record Official record
Conditions
Hyperkalemia
Interventions
RDX013, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 85 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Coral Gables, Florida • Miami Lakes, Florida • Miami Springs, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Jul 22, 2026, 9:18 AM EDT
Recruiting Phase 2 Interventional

Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age

NCT05766839
View directory record Official record
Conditions
Hyperkalemia
Interventions
Patiromer
Drug
Lead sponsor
Vifor Pharma, Inc.
Industry
Eligibility
0 Years to 11 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
13
States / cities
Aurora, Colorado • Jacksonville, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 22, 2026, 9:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Irradiated Blood Versus Non Irradiated Blood Transfusions in Craniosynostosis Repair

NCT02483702
View directory record Official record
Conditions
Graft Versus Host Disease, Hyperkalemia, Craniectomy, Synostectomy, FOA, Congenital Malformations
Interventions
Irradiated Blood Transfusions, Non-Irradiated Blood Transfusions
Other
Lead sponsor
Valley Anesthesiology Consultants
Other
Eligibility
2 Months to 6 Months
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Jul 22, 2026, 9:18 AM EDT
Completed Phase 2 Interventional Results available

The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia

NCT03326583
View directory record Official record
Conditions
ESRD, Hyperkalemia, End Stage Renal Disease
Interventions
Patiromer
Drug
Lead sponsor
Dominic Raj
Other
Eligibility
18 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Jul 22, 2026, 9:18 AM EDT
Terminated Phase 4 Interventional Results available

Comparison of Potassium Binders in the ER

NCT04585542
View directory record Official record
Conditions
Acute Hyperkalemia, Oral Potassium Binders
Interventions
Polyethylene Glycol 3350, Sodium Polystyrene Sulfonate Oral Suspension [SPS], Patiromer, Sodium zirconium cyclosilicate
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 22, 2026, 9:18 AM EDT
Completed Phase 4 Interventional

A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia

NCT05535920
View directory record Official record
Conditions
Hyperkalemia
Interventions
LOKELMA 5 GM Powder for Oral Suspension
Drug
Lead sponsor
NephroNet, Inc.
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
La Jolla, California • Lawrenceville, Georgia • Fort Wayne, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Jul 22, 2026, 9:18 AM EDT
Completed No phase listed Observational Results available

POtassium and Cardiac Rhythm Trends in MaintENance HemoDialysis: A Multicenter, Prospective, Observational Study

NCT02609841
View directory record Official record
Conditions
Hyperkalemia
Interventions
Cardiac rhythm remote monitoring system
Device
Lead sponsor
ZS Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Los Angeles, California • San Jose, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Jul 22, 2026, 9:18 AM EDT
Terminated Phase 4 Interventional Results available

Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia

NCT04997161
View directory record Official record
Conditions
Hyperkalaemia
Interventions
Sodium Zirconium Cyclosilicate (SZC), Enhanced dietary advice, Standard dietary advice including K+ restriction.
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Jul 22, 2026, 9:18 AM EDT
Terminated Phase 2 Interventional Results available

Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia

NCT03087058
View directory record Official record
Conditions
Hyperkalemia
Interventions
Patiromer
Drug
Lead sponsor
Vifor Pharma, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
10
States / cities
Palo Alto, California • Kansas City, Kansas • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Jul 22, 2026, 9:18 AM EDT
Completed Phase 3 Interventional Results available

Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)

NCT03888066
View directory record Official record
Conditions
Hyperkalemia
Interventions
Patiromer, Placebos
Drug
Lead sponsor
Vifor Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
133
States / cities
Alexander City, Alabama • Huntsville, Alabama • Phoenix, Arizona + 110 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Jul 22, 2026, 9:18 AM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.

NCT02088073
View directory record Official record
Conditions
Hyperkalemia
Interventions
Sodium zirconium cyclosilicate, Placebo
Drug
Lead sponsor
ZS Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
38
States / cities
Anniston, Alabama • Huntsville, Alabama • Scottsboro, Alabama + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Jul 22, 2026, 9:18 AM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia

NCT01737697
View directory record Official record
Conditions
Hyperkalemia
Interventions
Zirconium silicate (acute phase), Zirconium silicate (subacute phase), Placebo (acute phase), Placebo ( subacute phase)
Drug
Lead sponsor
ZS Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
754 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
42
States / cities
Anniston, Alabama • Huntsville, Alabama • Glendale, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Jul 22, 2026, 9:18 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Patiromer in Heart Failure Patients

NCT00868439
View directory record Official record
Conditions
Hyperkalemia, Heart Failure
Interventions
patiromer, placebo
Drug
Lead sponsor
Relypsa, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
9
States / cities
Miami, Florida • Port Charlotte, Florida • Peoria, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Jul 22, 2026, 9:18 AM EDT
Completed Phase 4 Interventional Results available

Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)

NCT02933450
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Patiromer 25.2 g
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Jul 22, 2026, 9:18 AM EDT
Terminated Phase 2 Interventional Results available

Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure

NCT03532009
View directory record Official record
Conditions
Heart Failure
Interventions
Sodium Zirconium Cyclosilicate, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 150 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
14
States / cities
National City, California • Stanford, California • Waterbury, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Jul 22, 2026, 9:18 AM EDT
Completed Phase 4 Interventional Results available

Patiromer With or Without Food for the Treatment of Hyperkalemia

NCT02694744
View directory record Official record
Conditions
Hyperkalemia
Interventions
patiromer
Drug
Lead sponsor
Relypsa, Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
29
States / cities
Fountain Valley, California • Huntington Beach, California • Palm Springs, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Jul 22, 2026, 9:18 AM EDT
Terminated Phase 3 Interventional Results available

Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

NCT04847232
View directory record Official record
Conditions
Hyperkalemia
Interventions
Sodium Zirconium Cyclosilicate (SZC), SZC Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
2,690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
57
States / cities
Huntsville, Alabama • Mesa, Arizona • Bakersfield, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Jul 22, 2026, 9:18 AM EDT